MGMT and neoplasm: First, imipramine may inhibit ERK/NF‐κB signalling transduction and thus reduced tumour progression‐related proteins expression, including MGMT, MMP‐2, MMP‐9, uPA, VEGF, Cyclin D1 and XIAP.